165 related articles for article (PubMed ID: 23681112)
1. Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma.
Machado I; López Guerrero JA; Navarro S; Mayordomo E; Scotlandi K; Picci P; Llombart-Bosch A
Virchows Arch; 2013 Jun; 462(6):665-71. PubMed ID: 23681112
[TBL] [Abstract][Full Text] [Related]
2. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
3. KPNA2 expression is a potential marker for differential diagnosis between osteosarcomas and other malignant bone tumor mimics.
Jiang L; Liu J; Wei Q; Wang Y
Diagn Pathol; 2020 Nov; 15(1):135. PubMed ID: 33176814
[TBL] [Abstract][Full Text] [Related]
4. Galectin-1 is a powerful marker to distinguish chondroblastic osteosarcoma and conventional chondrosarcoma.
Gomez-Brouchet A; Mourcin F; Gourraud PA; Bouvier C; De Pinieux G; Le Guelec S; Brousset P; Delisle MB; Schiff C
Hum Pathol; 2010 Sep; 41(9):1220-30. PubMed ID: 20399482
[TBL] [Abstract][Full Text] [Related]
5. FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma.
Lee AF; Hayes MM; Lebrun D; Espinosa I; Nielsen GP; Rosenberg AE; Lee CH
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):233-8. PubMed ID: 21084965
[TBL] [Abstract][Full Text] [Related]
6. Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors.
Machado I; Navarro S; Giner F; Alberghini M; Bertoni F; Llombart-Bosch A
Virchows Arch; 2010 Jul; 457(1):87-9. PubMed ID: 20552365
[No Abstract] [Full Text] [Related]
7. Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma.
Salas S; de Pinieux G; Gomez-Brouchet A; Larrousserie F; Leroy X; Aubert S; Decouvelaere AV; Giorgi R; Fernandez C; Bouvier C
Virchows Arch; 2009 Jan; 454(1):81-7. PubMed ID: 19050913
[TBL] [Abstract][Full Text] [Related]
8. Small cell osteosarcoma of bone: an immunohistochemical study with differential diagnostic considerations.
Devaney K; Vinh TN; Sweet DE
Hum Pathol; 1993 Nov; 24(11):1211-25. PubMed ID: 7503935
[TBL] [Abstract][Full Text] [Related]
9. Expression of podoplanin in human bone and bone tumors: New marker of osteogenic and chondrogenic bone tumors.
Ariizumi T; Ogose A; Kawashima H; Hotta T; Li G; Xu Y; Umezu H; Sugai M; Endo N
Pathol Int; 2010 Mar; 60(3):193-202. PubMed ID: 20403045
[TBL] [Abstract][Full Text] [Related]
10. sCD30 and sCD40L detection in patients with osteosarcoma, chondrosarcoma and Ewing sarcoma.
Solooki S; Khozaei A; Shamsdin SA; Emami MJ; Khademolhosseini F
Iran J Immunol; 2013 Dec; 10(4):229-37. PubMed ID: 24375064
[TBL] [Abstract][Full Text] [Related]
11. Type II collagen as specific marker for mesenchymal chondrosarcomas compared to other small cell sarcomas of the skeleton.
Müller S; Söder S; Oliveira AM; Inwards CY; Aigner T
Mod Pathol; 2005 Aug; 18(8):1088-94. PubMed ID: 15731776
[TBL] [Abstract][Full Text] [Related]
12. The impact of osteonectin for differential diagnosis of osteogenic bone tumors: an immunohistochemical and in situ hybridization approach.
Park YK; Yang MH; Park HR
Skeletal Radiol; 1996 Jan; 25(1):13-7. PubMed ID: 8717113
[TBL] [Abstract][Full Text] [Related]
13. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
[TBL] [Abstract][Full Text] [Related]
14. Bayesian pretest probability estimation for primary malignant bone tumors based on the Surveillance, Epidemiology and End Results Program (SEER) database.
Benndorf M; Neubauer J; Langer M; Kotter E
Int J Comput Assist Radiol Surg; 2017 Mar; 12(3):485-491. PubMed ID: 27722873
[TBL] [Abstract][Full Text] [Related]
15. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.
Kerr DA; Lopez HU; Deshpande V; Hornicek FJ; Duan Z; Zhang Y; Rosenberg AE; Borger DR; Nielsen GP
Am J Surg Pathol; 2013 Jun; 37(6):787-95. PubMed ID: 23598960
[TBL] [Abstract][Full Text] [Related]
16. Epithelial cell adhesion molecules and epithelial mesenchymal transition (EMT) markers in Ewing's sarcoma family of tumors (ESFTs). Do they offer any prognostic significance?
Machado I; López-Guerrero JA; Navarro S; Alberghini M; Scotlandi K; Picci P; Llombart-Bosch A
Virchows Arch; 2012 Sep; 461(3):333-7. PubMed ID: 22898789
[TBL] [Abstract][Full Text] [Related]
17. The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma.
Amary MF; Berisha F; Mozela R; Gibbons R; Guttridge A; O'Donnell P; Baumhoer D; Tirabosco R; Flanagan AM
Histopathology; 2016 Jul; 69(1):121-7. PubMed ID: 26844533
[TBL] [Abstract][Full Text] [Related]
18. FGF23 Expression Is a Promising Immunohistochemical Diagnostic Marker for Undifferentiated Pleomorphic Sarcoma of Bone (UPSb).
Al-Hassi HO; Ali NM; Cooke H; De Silva S; Brini AT; Babu P; Sumathi V; Morris MR; Niada S
Genes (Basel); 2024 Feb; 15(2):. PubMed ID: 38397231
[No Abstract] [Full Text] [Related]
19. NKX3.1 a useful marker for mesenchymal chondrosarcoma: An immunohistochemical study.
Syed M; Mushtaq S; Loya A; Hassan U
Ann Diagn Pathol; 2021 Feb; 50():151660. PubMed ID: 33302222
[TBL] [Abstract][Full Text] [Related]
20. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma].
Li M; Cai YP; Lu KY; Chen Y; Zhu X; Yin Y; Tang J
Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):631-5. PubMed ID: 27646893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
